Reported Earnings • Jul 24
Second quarter 2026 earnings released Second quarter 2026 results: Revenue: ₫119.1b (down 10.0% from 2Q 2025). Net income: ₫13.4b (down 40% from 2Q 2025). Profit margin: 11% (down from 17% in 2Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • May 11
First quarter 2026 earnings released: EPS: ₫1,859 (vs ₫2,432 in 1Q 2025) First quarter 2026 results: EPS: ₫1,859. Revenue: ₫138.6b (up 10% from 1Q 2025). Net income: ₫22.9b (up 1.0% from 1Q 2025). Profit margin: 17% (down from 18% in 1Q 2025). The decrease in margin was driven by higher expenses. Upcoming Dividend • Apr 14
Upcoming dividend of ₫1,400 per share Eligible shareholders must have bought the stock before 21 April 2026. Payment date: 06 May 2026. Payout ratio is a comfortable 36% but the company is not cash flow positive. Trailing yield: 1.7%. Lower than top quartile of Vietnamese dividend payers (7.7%). Lower than average of industry peers (5.0%). New Risk • Mar 18
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Vietnamese stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.4% average weekly change). High level of non-cash earnings (98% accrual ratio). Minor Risk Market cap is less than US$100m (₫1.33t market cap, or US$50.7m). Announcement • Feb 04
Pharmedic Pharmaceutical Medicinal Joint Stock Company, Annual General Meeting, Mar 28, 2026 Pharmedic Pharmaceutical Medicinal Joint Stock Company, Annual General Meeting, Mar 28, 2026. Reported Earnings • Jan 22
Full year 2025 earnings released: EPS: ₫6,438 (vs ₫6,268 in FY 2024) Full year 2025 results: EPS: ₫6,438 (up from ₫6,268 in FY 2024). Revenue: ₫546.6b (up 9.7% from FY 2024). Net income: ₫82.3b (up 41% from FY 2024). Profit margin: 15% (up from 12% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Nov 12
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₫165,200, the stock trades at a trailing P/E ratio of 24.6x. Average trailing P/E is 16x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders of 272% over the past three years. Valuation Update With 7 Day Price Move • Oct 29
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₫144,400, the stock trades at a trailing P/E ratio of 21.5x. Average trailing P/E is 16x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders of 242% over the past three years. Reported Earnings • Oct 23
Third quarter 2025 earnings released: EPS: ₫1,572 (vs ₫1,743 in 3Q 2024) Third quarter 2025 results: EPS: ₫1,572 (down from ₫1,743 in 3Q 2024). Revenue: ₫126.5b (up 3.1% from 3Q 2024). Net income: ₫19.4b (down 9.8% from 3Q 2024). Profit margin: 15% (down from 18% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Sep 02
Upcoming dividend of ₫3,868 per share Eligible shareholders must have bought the stock before 09 September 2025. Payment date: 22 September 2025. Payout ratio is a comfortable 20% but the company is not cash flow positive. Trailing yield: 2.3%. Lower than top quartile of Vietnamese dividend payers (7.4%). Lower than average of industry peers (5.0%). Reported Earnings • Jul 23
Second quarter 2025 earnings released: EPS: ₫1,814 (vs ₫1,961 in 2Q 2024) Second quarter 2025 results: EPS: ₫1,814 (down from ₫1,961 in 2Q 2024). Revenue: ₫132.3b (down 3.6% from 2Q 2024). Net income: ₫22.4b (down 7.5% from 2Q 2024). Profit margin: 17% (in line with 2Q 2024). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Apr 19
First quarter 2025 earnings released: EPS: ₫1,841 (vs ₫1,192 in 1Q 2024) First quarter 2025 results: EPS: ₫1,841 (up from ₫1,192 in 1Q 2024). Revenue: ₫125.7b (up 24% from 1Q 2024). Net income: ₫22.7b (up 54% from 1Q 2024). Profit margin: 18% (up from 14% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Mar 25
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. Payout ratio: 103% Cash payout ratio: 464% Dividend yield: 17% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 103% Cash payout ratio: 464% High level of non-cash earnings (48% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Market cap is less than US$100m (₫1.04t market cap, or US$40.6m). Upcoming Dividend • Mar 14
Upcoming dividend of ₫1,400 per share Eligible shareholders must have bought the stock before 21 March 2025. Payment date: 08 April 2025. Payout ratio is on the higher end at 82%, and the cash payout ratio is above 100%. Trailing yield: 16%. Within top quartile of Vietnamese dividend payers (7.6%). Higher than average of industry peers (4.5%). Announcement • Mar 07
Pharmedic Pharmaceutical Medicinal Joint Stock Company, Annual General Meeting, Apr 19, 2025 Pharmedic Pharmaceutical Medicinal Joint Stock Company, Annual General Meeting, Apr 19, 2025. Upcoming Dividend • Feb 11
Upcoming dividend of ₫5,400 per share Eligible shareholders must have bought the stock before 18 February 2025. Payment date: 28 February 2025. Payout ratio is on the higher end at 82%, and the cash payout ratio is above 100%. Trailing yield: 15%. Within top quartile of Vietnamese dividend payers (7.7%). Higher than average of industry peers (4.5%). New Risk • Jan 21
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 48% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (48% accrual ratio). Minor Risks Dividend is not well covered by cash flows (454% cash payout ratio). Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (₫1.11t market cap, or US$44.2m). Reported Earnings • Jan 21
Full year 2024 earnings released: EPS: ₫6,268 (vs ₫6,536 in FY 2023) Full year 2024 results: EPS: ₫6,268. Revenue: ₫498.2b (up 2.7% from FY 2023). Net income: ₫80.1b (up 31% from FY 2023). Profit margin: 16% (up from 13% in FY 2023). The increase in margin was primarily driven by higher revenue. Valuation Update With 7 Day Price Move • Dec 31
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₫104,000, the stock trades at a trailing P/E ratio of 15.5x. Average trailing P/E is 17x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders of 123% over the past three years. Upcoming Dividend • Dec 05
Upcoming dividend of ₫5,500 per share Eligible shareholders must have bought the stock before 12 December 2024. Payment date: 25 December 2024. Payout ratio is on the higher end at 82%, and the cash payout ratio is above 100%. Trailing yield: 15%. Within top quartile of Vietnamese dividend payers (8.2%). Higher than average of industry peers (4.2%). Valuation Update With 7 Day Price Move • Dec 04
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₫128,700, the stock trades at a trailing P/E ratio of 19.2x. Average trailing P/E is 17x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders of 163% over the past three years. Valuation Update With 7 Day Price Move • Nov 13
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₫111,600, the stock trades at a trailing P/E ratio of 16.7x. Average trailing P/E is 16x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders of 125% over the past three years. Reported Earnings • Oct 19
Third quarter 2024 earnings released: EPS: ₫1,743 (vs ₫1,684 in 3Q 2023) Third quarter 2024 results: EPS: ₫1,743 (up from ₫1,684 in 3Q 2023). Revenue: ₫122.7b (down 16% from 3Q 2023). Net income: ₫21.5b (up 3.5% from 3Q 2023). Profit margin: 18% (up from 14% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 14% per year. New Risk • Aug 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Vietnamese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 211% Cash payout ratio: 162% Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Market cap is less than US$100m (₫825.0b market cap, or US$33.0m). Reported Earnings • Jul 18
Second quarter 2024 earnings released: EPS: ₫1,961 (vs ₫1,861 in 2Q 2023) Second quarter 2024 results: EPS: ₫1,961 (up from ₫1,861 in 2Q 2023). Revenue: ₫137.2b (up 32% from 2Q 2023). Net income: ₫24.2b (up 5.4% from 2Q 2023). Profit margin: 18% (down from 22% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 12% per year. Reported Earnings • Apr 24
First quarter 2024 earnings released: EPS: ₫1,192 (vs ₫1,624 in 1Q 2023) First quarter 2024 results: EPS: ₫1,192 (down from ₫1,624 in 1Q 2023). Revenue: ₫101.2b (down 1.9% from 1Q 2023). Net income: ₫14.7b (down 3.0% from 1Q 2023). Profit margin: 14% (in line with 1Q 2023). Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 7% per year. Upcoming Dividend • Mar 11
Upcoming dividend of ₫1,400 per share Eligible shareholders must have bought the stock before 18 March 2024. Payment date: 01 April 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 19%. Within top quartile of Vietnamese dividend payers (8.5%). Higher than average of industry peers (3.6%). Upcoming Dividend • Nov 30
Upcoming dividend of ₫4,600 per share at 3.4% yield Eligible shareholders must have bought the stock before 07 December 2023. Payment date: 22 December 2023. Payout ratio is a comfortable 47% and this is well supported by cash flows. Trailing yield: 3.4%. Lower than top quartile of Vietnamese dividend payers (8.9%). In line with average of industry peers (3.5%). Upcoming Dividend • Nov 02
Upcoming dividend of ₫8,000 per share at 3.3% yield Eligible shareholders must have bought the stock before 09 November 2023. Payment date: 24 November 2023. Payout ratio is a comfortable 38% and this is well supported by cash flows. Trailing yield: 3.3%. Lower than top quartile of Vietnamese dividend payers (9.5%). In line with average of industry peers (3.5%). Reported Earnings • Oct 18
Third quarter 2023 earnings released: EPS: ₫1,684 (vs ₫1,653 in 3Q 2022) Third quarter 2023 results: EPS: ₫1,684 (up from ₫1,653 in 3Q 2022). Revenue: ₫146.1b (up 20% from 3Q 2022). Net income: ₫20.8b (up 1.9% from 3Q 2022). Profit margin: 14% (down from 17% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 14% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Sep 29
New major risk - Revenue and earnings growth Earnings have declined by 0.04% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 0.04% per year over the past 5 years. High level of non-cash earnings (33% accrual ratio). Minor Risk Market cap is less than US$100m (₫694.3b market cap, or US$28.6m). Valuation Update With 7 Day Price Move • Sep 13
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₫88,000, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 14x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders of 67% over the past three years. Upcoming Dividend • Sep 12
Upcoming dividend of ₫1,600 per share at 3.0% yield Eligible shareholders must have bought the stock before 19 September 2023. Payment date: 29 September 2023. Payout ratio is a comfortable 22% but the company is paying out more than the cash it is generating. Trailing yield: 3.0%. Lower than top quartile of Vietnamese dividend payers (8.4%). In line with average of industry peers (3.2%). Reported Earnings • Jul 19
Second quarter 2023 earnings released: EPS: ₫1,861 (vs ₫1,749 in 2Q 2022) Second quarter 2023 results: EPS: ₫1,861 (up from ₫1,749 in 2Q 2022). Revenue: ₫103.7b (down 3.2% from 2Q 2022). Net income: ₫22.9b (up 6.4% from 2Q 2022). Profit margin: 22% (up from 20% in 2Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 8% per year. Reported Earnings • Apr 19
First quarter 2023 earnings released: EPS: ₫1,230 (vs ₫1,980 in 1Q 2022) First quarter 2023 results: EPS: ₫1,230 (down from ₫1,980 in 1Q 2022). Revenue: ₫103.2b (down 12% from 1Q 2022). Net income: ₫15.2b (down 18% from 1Q 2022). Profit margin: 15% (down from 16% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 10% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Mar 29
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₫77,900, the stock trades at a trailing P/E ratio of 8.7x. Average trailing P/E is 12x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders of 125% over the past three years. Upcoming Dividend • Mar 10
Upcoming dividend of ₫1,400 per share at 3.6% yield Eligible shareholders must have bought the stock before 17 March 2023. Payment date: 03 April 2023. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 3.6%. Lower than top quartile of Vietnamese dividend payers (9.1%). In line with average of industry peers (3.8%). Reported Earnings • Jan 19
Full year 2022 earnings released: EPS: ₫6,525 (vs ₫5,066 in FY 2021) Full year 2022 results: EPS: ₫6,525 (up from ₫5,066 in FY 2021). Revenue: ₫472.3b (up 14% from FY 2021). Net income: ₫83.4b (up 77% from FY 2021). Profit margin: 18% (up from 11% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Dec 29
Investor sentiment improved over the past week After last week's 16% share price gain to ₫81,900, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 12x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders of 77% over the past three years. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Oct 16
Third quarter 2022 earnings released: EPS: ₫1,653 (vs ₫246 in 3Q 2021) Third quarter 2022 results: EPS: ₫1,653 (up from ₫246 in 3Q 2021). Revenue: ₫121.5b (up 164% from 3Q 2021). Net income: ₫20.4b (up ₫17.3b from 3Q 2021). Profit margin: 17% (up from 6.6% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Sep 29
Investor sentiment improved over the past week After last week's 18% share price gain to ₫73,500, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 15x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders of 34% over the past three years. Upcoming Dividend • Aug 24
Upcoming dividend of ₫1,000 per share Eligible shareholders must have bought the stock before 31 August 2022. Payment date: 20 September 2022. Payout ratio is a comfortable 26% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of Vietnamese dividend payers (7.4%). In line with average of industry peers (3.6%). Reported Earnings • Jul 20
Second quarter 2022 earnings released: EPS: ₫1,749 (vs ₫1,617 in 2Q 2021) Second quarter 2022 results: EPS: ₫1,749 (up from ₫1,617 in 2Q 2021). Revenue: ₫107.1b (down 4.9% from 2Q 2021). Net income: ₫21.6b (up 8.1% from 2Q 2021). Profit margin: 20% (up from 18% in 2Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has remained flat. Board Change • Apr 29
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Upcoming Dividend • Mar 11
Upcoming dividend of ₫1,400 per share Eligible shareholders must have bought the stock before 18 March 2022. Payment date: 04 April 2022. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 3.6%. Lower than top quartile of Vietnamese dividend payers (5.8%). In line with average of industry peers (3.3%). Reported Earnings • Oct 20
Third quarter 2021 earnings released The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₫46.0b (down 59% from 3Q 2020). Net income: ₫3.04b (down 84% from 3Q 2020). Profit margin: 6.6% (down from 16% in 3Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 1% per year. Announcement • Sep 21
An unknown buyer acquired 6.73% stake in Pharmedic Pharmaceutical Medicinal Joint Stock Company (HNX:PMC). An unknown buyer acquired 6.73% stake in Pharmedic Pharmaceutical Medicinal Joint Stock Company (HNX:PMC) on September 6, 2021. After completion America LLC will hold 300 shares.
An unknown buyer completed the acquisition of 6.73% stake in Pharmedic Pharmaceutical Medicinal Joint Stock Company (HNX:PMC) on September 6, 2021. Reported Earnings • Jul 15
Second quarter 2021 earnings released: EPS ₫1,617 (vs ₫1,318 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: ₫112.6b (up 24% from 2Q 2020). Net income: ₫19.9b (up 23% from 2Q 2020). Profit margin: 18% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 5% per year. Reported Earnings • Apr 20
First quarter 2021 earnings released: EPS ₫1,406 (vs ₫2,209 in 1Q 2020) The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₫116.5b (down 9.3% from 1Q 2020). Net income: ₫17.3b (down 16% from 1Q 2020). Profit margin: 15% (down from 16% in 1Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 6% per year. Upcoming Dividend • Mar 12
First Dividend Is ₫1,400 Per Share Will be paid on the 5th of April to those who are registered shareholders by the 19th of March. The company last paid an ordinary dividend in February 2014. The average dividend yield among industry peers is 3.6%. Reported Earnings • Jan 21
Full year 2020 earnings released: EPS ₫5,837 The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: ₫460.8b (flat on FY 2019). Net income: ₫74.6b (up 37% from FY 2019). Profit margin: 16% (up from 12% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 3% per year. Is New 90 Day High Low • Jan 04
New 90-day high: ₫58,100 The company is up 4.0% from its price of ₫55,900 on 06 October 2020. The Vietnamese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period. Reported Earnings • Oct 20
Third quarter earnings released Over the last 12 months the company has reported total profits of ₫55.1b, up 2.6% from the prior year. Total revenue was ₫457.8b over the last 12 months, largely unchanged from the prior year. Is New 90 Day High Low • Oct 13
New 90-day low: ₫50,100 The company is down 10.0% from its price of ₫55,500 on 15 July 2020. The Vietnamese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 8.0% over the same period.